Luo Yehao, Xu Donghan, Fu Yulei, Tang Xiusong, Chen Zhenfeng, Huang An, Pang Yuzhou, Zhang Yunyan, Li Renfeng
The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, Guangxi Province.
Macau University of Science and Technology, Macau.
Medicine (Baltimore). 2020 Oct 2;99(40):e22404. doi: 10.1097/MD.0000000000022404.
Systemic lupus erythematosus (SLE), known as lupus, is a chronic autoimmune disease and there is no cure for SLE. The western medication can improve syndromes to some extent; however, severe adverse drug reactions appear at the same time. Recently, it is confirmed that Chinese medicine also can have an excellent clinical efficacy on SLE.
The following databases will be searched for relevant information before July 2020: PubMed, Embase, Cochrane Library, Web of Science, and China National Knowledge Infrastructure.
levels of total remission rate, SLEDAI. Secondary results: The laboratory index about C3 levels, Hb levels, white blood cell levels, and adverse event. Data will be collected independently by 2 researchers, and the risk of bias in meta analysis will be evaluated according to "Cochrane Handbook for Systematic Reviews of Interventions." All data analysis will be conducted using Review Manager V.5.3. and Stata V.12.0.
The curative effect and safety of Chinese herbal compound prescription treatment for SLE patients will be evaluated systematically.
The systematic review of this study will summarize the currently published evidence of Chinese herbal compound prescription treatment for SLE to further guide its promotion and application.
The private information from individuals will not be published. This systematic review also will not involve endangering participant rights. Ethical approval is not required. The results may be published in a peer-reviewed journal or disseminated in relevant conferences. OPEN SCIENCE FRAMEWORK (OSF)REGISTRATION NUMBER:: https://osf.io/wvfrx/.
系统性红斑狼疮（SLE），即狼疮，是一种慢性自身免疫性疾病，目前无法治愈。西药虽能在一定程度上改善症状，但同时会出现严重的药物不良反应。近年来，证实中药治疗SLE也具有良好的临床疗效。
检索以下数据库以获取2020年7月之前的相关信息：PubMed、Embase、Cochrane图书馆、科学网和中国知网。
总缓解率、SLEDAI水平。次要结果：关于C3水平、血红蛋白水平、白细胞水平的实验室指标以及不良事件。数据将由两名研究人员独立收集，荟萃分析中的偏倚风险将根据《Cochrane系统评价干预措施手册》进行评估。所有数据分析将使用Review Manager V.5.3和Stata V.12.0进行。
将系统评价中药复方治疗SLE患者的疗效和安全性。
本研究的系统评价将总结目前已发表的中药复方治疗SLE的证据，以进一步指导其推广应用。
不会公布个人隐私信息。本系统评价也不会涉及危及参与者权利的问题。无需伦理批准。结果可能发表在同行评审期刊上或在相关会议上传播。开放科学框架（OSF）注册号：https://osf.io/wvfrx/ 。
